PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 4, 2014, Pages 423-429

  Rosser, G ^a,b   Tricoci, P ^c   Morrow, D ^d   Christopoulos, C ^b,e   Niespialowska Steuden, M N ^a,b   Kozarski, R ^e   Wilcox, R ^f   Gorog, D A ^a,b,e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

PAR 1 antagonist; Platelets; Thrombolysis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; NITRATE; PLACEBO; THROMBIN RECEPTOR ACTIVATING PEPTIDE; VORAPAXAR; LACTONE; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD SAMPLING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEMATOCRIT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOSIS; ANTAGONISTS AND INHIBITORS; CORONARY DISEASE; DOUBLE BLIND PROCEDURE; LONGITUDINAL STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRIDINES; RECEPTOR, PAR-1; THROMBOSIS;

EID: 84910108335     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1075-4     Document Type: Article

References (20)

1. Barrabes JA, Galian L (2010) Endogenous thrombolysis. J Am Col Cardiol 55(19):2116–2117
2. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933
3. Gorog DA, Fuster V (2013) Platelet function tests in clinical cardiology. J Am Coll Cardiol 61:2115–2129
4. Sweeny JM, Gorog DA, Fuster V (2009) Antiplatelet drug “resistance”. Part 1. Mechanisms and clinical measurements. Nat Rev Cardiol 6:273–282
5. Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA (2010) Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 55(19):2107–2115
6. Sharma S, Farrington K, Kozarski R et al (2013) Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J 34(5):354–363
7. Taomoto K, Ohnishi H, Kuga Y et al (2010) Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test. Pathophysiol Haemost Thromb 37(1):43–48
8. Nakajima S, Noguchi T, Taka T et al (2000) A global platelet test of thrombosis and thrombolysis detects a prothrombotic state in some patients with non-insulin dependent diabetes and in some patients with stroke. Platelets 11(8):459–466
9. Bodary PF, Wickenheiser KJ, Eitzman DT (2002) Recent advances in under-standing endogenous fibrinolysis: implications for molecular-based treatment of vascular disorders. Expert Rev Mol Med 4:1–10
10. Taher TH, Stang L, Gordon PA et al (2004) Clopidogrel does not induce fibrinolysis in healthy subjects. Thromb Res 114:97–100
11. Kovacs IB, Gorog DA, Yamamoto J (2006) Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis 21:221–227
12. Tousoulis D, Antoniades C, Bosinakou E et al (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91(1):27–31
13. Undas A, Celinska-Löwenhoff M, Löwenhoff T et al (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4(5):1029–1036
14. Gorog DA (2010) Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 55(24):2701–2709
15. Bouma BN, Mosnier LO (2006) Thrombin activatable fibrinolysis inhibitor (TAFI)—how does thrombin regulate fibrinolysis? Ann Med 38(6):378–388
16. Becker RC, Moliterno DJ, Jennings LK et al (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919–928
17. Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366(1):20–33
18. Morrow DA, Braunwald E, Bonaca MP et al (2012) TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404–1413
19. Yamamoto J, Yamashita T, Ikarugi H et al (2003) Gorog thrombosis test: a global in vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis 14:31–39
20. Gorog DA, Yamamoto J, Saraf S et al (2011) The first direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the “Japanese paradox”. Int J Cardiol 152:43–48